Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 4/20 | 0.39 |
| ▸ | HTR2C | P28335 | 1/20 | 0.39 |
| ▸ | ABCC1 | P33527 | 1/20 | 0.39 |
| ▸ | GHSR | Q92847 | 3/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.38 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.38 |
| ▸ | PTGER4 | P35408 | 2/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | OPRL1 | P41146 | 3/20 | 0.36 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.36 |
| ▸ | AVPR1A | P37288 | 2/20 | 0.36 |
| ▸ | PDE5A | O76074 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2464052 | 0.89 | CHRNA7 (0.40) | CHRNA7MAPTMAPK1OPRL1OPRM1 | |
| SCHEMBL6886464 | 0.89 | AVPR1A (0.46) | AVPR1A | |
| SCHEMBL2463488 | 0.83 | AVPR1A (0.38) | CHRNA7AVPR1A | |
| SCHEMBL2461835 | 0.83 | AVPR1B (0.53) | AVPR1A | |
| SCHEMBL6888452 | 0.83 | AVPR1A (0.46) | ALOX5AVPR1A | |
| SCHEMBL6888896 | 0.82 | AVPR1A (0.42) | AVPR1A | |
| SCHEMBL6886578 | 0.79 | AVPR1A (0.44) | AVPR1A | |
| SCHEMBL6887453 | 0.78 | CHRNA7 (0.44) | KCNH2CHRNA7MAPTMAPK1 | |
| SCHEMBL6887450 | 0.78 | CHRNA7 (0.43) | CYP2D6GHSRKCNH2CHRNA7 | |
| SCHEMBL6886634 | 0.77 | AVPR1B (0.44) | AVPR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8841289-B2 | Heterocyclic derivatives | MERCK SHARP & DOHME B.V. (US) | 2014-09-23 | — | — | US | disclosed |
| US-8841289-B2 | Heterocyclic derivatives | MERCK SHARP & DOHME B.V. (US) | 2014-09-23 | — | — | US | disclosed |
| US-8841289-B2 | Heterocyclic derivatives | MERCK SHARP & DOHME B.V. (US) | 2014-09-23 | — | — | US | disclosed |
| US-20120208796-A1 | HETEROCYCLIC DERIVATIVES | ORGANON BIOSCIENCES NEDERLAND B.V. (NL) | 2012-08-16 | — | — | US | disclosed |
| US-20120208796-A1 | HETEROCYCLIC DERIVATIVES | ORGANON BIOSCIENCES NEDERLAND B.V. (NL) | 2012-08-16 | — | — | US | disclosed |
| US-20120208796-A1 | HETEROCYCLIC DERIVATIVES | ORGANON BIOSCIENCES NEDERLAND B.V. (NL) | 2012-08-16 | — | — | US | disclosed |
| WO-2011045258-A1 | CONDENSED AZINE - DERIVATIVES FOR THE TREATMENT OF DISEASES RELATED TO THE ACETYLCHOLINE RECEPTOR | N.V. ORGANON (NL) | 2011-04-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120208796-A1 | HETEROCYCLIC DERIVATIVES | CHRNA5, CHRM5, CHRNA7 | CYP2D6 265/4885HTR2C 75/4885ABCC1 2307/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.